Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 5/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | IDH2 | P48735 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896211 | 0.76 | ALDH1A1 (0.41) | CBLBIDH1IDH2MMP13ACACB | |
| SCHEMBL9927077 | 0.75 | IDH1 (0.40) | CBLBIDH1IDH2MMP13ACACB | |
| SCHEMBL14677116 | 0.73 | P2RX7 (0.42) | — | |
| SCHEMBL28018942 | 0.72 | IDH1 (0.41) | CBLBIDH1IDH2MMP13MALT1 | |
| SCHEMBL22924538 | 0.71 | CBLB (0.45) | CBLBIDH1IDH2MMP13ACACB | |
| SCHEMBL25211384 | 0.71 | CA2 (0.36) | ACACB | |
| SCHEMBL1578155 | 0.71 | KDM4E (0.49) | MALT1 | |
| SCHEMBL30307646 | 0.70 | IDH1 (0.35) | IDH1IDH2MALT1AAK1 | |
| SCHEMBL28956111 | 0.70 | IDH1 (0.35) | IDH1IDH2MALT1AAK1 | |
| SCHEMBL2791548 | 0.70 | KMT2A (0.47) | CBLBMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | CBLB 1119/4885IDH1 4236/4885IDH2 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.